News Posts List
Exploratory data presented for Active Biotech's ANYARA project
02/11/2010
The drug candidate ANYARA, using the TTS technology, is currently in pivotal Phase III clinical trials for Renal Cell Cancer. The primary endpoint is overall survival and results from these studies are expected first half of 2011.
Rexahn: The Undiscovered Biotech
02/11/2010
Archexin for Cancer: A first-in-class AKT Inhibitor for glioblastoma, pancreatic, stomach, ovarian, & renal cell cancers, as well as other solid tumors. Incredibly, the FDA granted orphan drug status in all 5 tumor types for this drug. It significantly reduces production of AKT protein via inhibition of AKT mRNA.
Report Backs EPA Classification Of PERC As Likely Human Carcinogen And Toxic To Nervous System
02/11/2010
This debate is reflected in the committee's examination of which possible PERC-related cancer -- leukemia, liver tumors, or kidney cancer -- provides the strongest data for EPA to estimate its cancer potential.
Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma
02/11/2010
In metastatic renal cell carcinoma combinations of interferon alfa-2a, interleukin-2, and fluorouracil produce higher response rates and longer progression-free survival than do single agents. We aimed to compare overall survival in patients receiving combination treatment or interferon alfa-2a.
Stereotactic percutaneous cryoablation for renal tumors
02/11/2010
Percutaneous imaging guided tumor ablation has an increasingly prominent role as minimally invasive treatment for renal tumors. Precise cryoprobe placement is essential for successful ablation. CT-Nav(R) is a novel stereotactic surgical navigation system with the potential to achieve precise percutaneous cryoprobe placement while decreasing radiation exposure compared to conventional computerized tomography guided procedures.
Trial patient: Afinitor 'saved my life'
02/10/2010
Trial patient and cancer sufferer Dave Saunders says a drug banned by UK's NICE saved his life.
Court rejects Bayer's appeal
02/10/2010
A division bench of Delhi high court on Tuesday dismissed Bayer's appeal against a judgment on an anti-cancer drug delivered by Justice Ravindra Bhat in August last year. The judgement rejected Bayer's attempt to introduce patent linkage system in the country a policy change, through a court direction. Patent linkage is against public health interests as it will delay the entry of cheaper generic medicines into the market and keep medicines out of reach of those who need them.
Terminally ill patients 'being penalised by Nice for having rare conditions'
02/10/2010
Terminally ill patients are being penalised for having rare conditions charities have warned after a kidney cancer medication was ruled too expensive for the NHS.
US HIFU Partners with Riverside Research Institute to Add Cancer Targeting Technology to HIFU Treatment
02/10/2010
US HIFU, a worldwide leader in the development, distribution and use of minimally invasive high intensity focused ultrasound (HIFU) technologies, announced today its exclusive partnership with Riverside Research Institute (RRI) to develop and test an ultrasonic method of prostate imaging and treatment that combines advanced tissue-type imaging with ultrasound energy from the Sonablate(R) 500 medical device.
UK firm gets final green light for stem cell trial
02/10/2010
The first patient in the study is now expected to receive treatment through the National Health Service.
News Feed